General Information of Drug (ID: DM5KAH6)

Drug Name
1-(2-Isopropoxy-phenyl)-piperazine
Synonyms
1-(2-isopropoxyphenyl)piperazine; 1-(2-Isopropoxy-phenyl)-piperazine; CHEMBL9669; 54013-91-1; 2-isopropoxyphenyl piperazine; SCHEMBL3867980; CTK1F9762; DTXSID40449277; QJULELIONYLITF-UHFFFAOYSA-N; ZINC26001539; BDBM50017448; 1-[2-(methylethoxy)phenyl]piperazine; AKOS010941535; N-[2-(1-methylethoxy)phenyl]piperazine; 1-[2-(1-methylethoxy)phenyl]piperazine; DA-05081; BC4321135; Piperazine, 1-[2-(1-methylethoxy)phenyl]-; FT-0741526
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 220.31
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C13H20N2O
IUPAC Name
1-(2-propan-2-yloxyphenyl)piperazine
Canonical SMILES
CC(C)OC1=CC=CC=C1N2CCNCC2
InChI
InChI=1S/C13H20N2O/c1-11(2)16-13-6-4-3-5-12(13)15-9-7-14-8-10-15/h3-6,11,14H,7-10H2,1-2H3
InChIKey
QJULELIONYLITF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10944016
CAS Number
54013-91-1
TTD ID
D0E2FY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [1]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 2.18E-01 -0.11 -0.51
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6.